The therapy survodutide works by reducing appetite while also targeting metabolism in the liver, representing a novel ...
Boehringer Ingelheim today announced that up to 83.0% of adults treated with survodutide (BI 456906) achieved a statistically significant improvement of metabolic dysfunction-associated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results